Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun;19(2):191-200.
doi: 10.1007/s40268-019-0270-3.

Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials

Lara Dennie  1
Affiliations
Clinical Trial

Safety and Efficacy of 0.5% Carbomer 980 Gel for Treatment of Symptoms of Common Cold: Results of 2 Randomized Trials

Lara Dennie. Drugs R D. 2019 Jun.

Erratum in

Abstract

Background: Two studies of intranasal 0.5% carbomer 980 gel were conducted evaluating nasal tolerability in healthy volunteers and safety and efficacy in adults with common cold symptoms.

Methods: Study 1 randomly assigned healthy adults to 0.5% carbomer 980 gel (n = 20) or placebo (n = 10) administered intranasally four times daily for 7 days. Nasal examinations were conducted at baseline and daily throughout the study. The primary endpoint was local nasal tolerability. Study 2 randomly assigned adults with an investigator-confirmed diagnosis of symptomatic common cold to 0.5% carbomer 980 gel (n = 87) or placebo (n = 81), administered intranasally four times daily for 7 days (except for day 1, where subjects who received their first dose mid-day administered only three doses). The primary efficacy endpoint was the average nasal symptom score over days 1‒4 (ANSS1-4). Secondary efficacy endpoints included ANSS over days 1‒7 and average total symptom score (ATSS). Adverse events (AEs) were recorded throughout the study.

Results: In study 1, subjects assigned to 0.5% carbomer 980 gel had no mucosal grading higher than grade 1B (superficial nasal mucosal erosion) and low incidences of mucosal bleeding and crusting. In study 2, there were no statistically significant differences between treatments for any efficacy endpoints. Active treatment was well-tolerated; the most commonly reported AEs were headache, myalgia, and cough.

Conclusion: While 0.5% carbomer 980 gel nasal spray demonstrated good local nasal tolerability in healthy volunteers, the spray did not significantly impact the course of infection or resolution of cold symptoms in subjects with common cold.

PubMed Disclaimer

Conflict of interest statement

Gilbert Shanga and Lara Dennie are employees of GlaxoSmithKline Consumer Healthcare.

Figures

Fig. 1
Fig. 1
Subject flow in study 1
Fig. 2
Fig. 2
Shift from baseline to last visit in nasal mucosal grade in healthy volunteers (study 1)
Fig. 3
Fig. 3
Highest nasal mucosal grade recorded during treatment period in healthy volunteers (study 1)
Fig. 4
Fig. 4
Subject flow in study 2. mITT modified intent-to-treat
See this image and copyright information in PMC

References

    1. Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. CMAJ. 2014;186:190–199. doi: 10.1503/cmaj.121442. - DOI - PMC - PubMed
    1. Hull JD, Barton IP, Torgersen J, McNeil CM. A survey of the experience and impact of acute upper respiratory tract infections on people in six countries in the 2011/2012 common cold and flu season. Open J Respir Dis. 2013;3:175–187.
    1. Kennedy JL, Turner RB, Braciale T, Heymann PW, Borish L. Pathogenesis of rhinovirus infection. Curr Opin Virol. 2012;2:287–293. doi: 10.1016/j.coviro.2012.03.008. - DOI - PMC - PubMed
    1. Turner RB, Hendley JO, Gwaltney JM., Jr Shedding of infected ciliated epithelial cells in rhinovirus colds. J Infect Dis. 1982;145:849–853. doi: 10.1093/infdis/145.6.849. - DOI - PubMed
    1. Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med. 1989;65:145–160. - PMC - PubMed

Publication types